Mergers and acquisitions of life science companies that find their way into this space normally involve some combination of famous executives, billions of dollars, or the commercial fate of a medical miracle.
This one is different. Chances are you’ve never heard of Semprus Biosciences of Cambridge or the bigger company that bought it Monday for relatively modest money. The medical technology, though important, is no miracle. The main reason Semprus chief executive David Lucchino’s name may ring a bell is that he happens to be the nephew of Boston Red Sox president Larry Lucchino.